Progress in the diagnosis and treatment of elderly patients with acute myeloid leukemia
-
-
Key words:
- acute myeloid leukemia /
- elderly /
- diagnosis /
- treatment
-
-
[1] 吴迪,李秋柏.老年急性髓细胞白血病的治疗进展[J].国际输血及血液学杂志,2019,42(6):524-529.
[2] Bullinger L,D9hner K,D9hner H.Genomics of Acute Myeloid Leukemia Diagnosis and Pathways[J].J Clin Oncol,2017,35(9):934-946.
[3] Burd A,Levine RL,Ruppert AS,et al.Precision Medicine Treatment in Older AML:Results of Beat AMLMaster Trial[J].Blood,2019,134:175.
[4] 李军民.老年急性髓系白血病患者的治疗策略[J].临床血液学杂志,2019,32(5):327-331.
[5] Chen EC,Garcia JS.Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?[J].Hematology Am Soc Hematol Educ Program,2020,2020(1):41-50.
[6] Lin TL,Rizzieri DA,Ryan DH,et al.Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351:phase 3post hoc analyses[J].Blood Adv,2021,5(6):1719-1728.
[7] Chiche E,RahméR,Bertoli S,et al.Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients:a multicentric French cohort[J].Blood Adv,2021,5(1):176-184.
[8] Chua CC,Roberts AW,Reynolds J,et al.Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial(CAVEAT):A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy[J].J Clin Oncol,2020,38(30):3506-3517.
[9] 李秋柏,吴迪.老年急性髓系白血病去甲基化药物治疗新进展[J].临床血液学杂志,2020,33(5):307-311.
[10] Labrador J,Martínez-Cuadrón D,Fuente A,et al.Azacitidine Vs.Decitabine in Unfit Newly Diagnosed A-cute Myeloid Leukemia Patients:Results from the Pethema Registry[J].Blood,2020,136:25-27.
[11] Salamero O,Somervaille T,Molero A,et al.Robust Efficacy Signals in Elderly AML Patients Treated with Iadademstat in Combination with Azacitidine(ALICE Phase IIa Trial)[J].Blood,2020,136:22.
[12] Botton S,Cluzeau T,Vigil CE,et al.SY-1425,a Potent and Selective RARαAgonist,in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia[J].Blood,2020,136:4-5.
[13] Sekeres MA,Watts J,Radinoff A,et al.Randomized phase 2trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML[J].Leukemia.2021 Jan 22.doi:10.1038/s41375-021-01125-4.[online ahead of print].
[14] DiNardo CD,Maiti A,Rausch CR,et al.10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible,and relapsed or refractory acute myeloid leukaemia:a single-centre,phase 2trial[J].Lancet Haematol,2020,7(10):e724-e736.
[15] Maiti A,DiNardo CD,Wang SA,et al.Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia[J].Blood,2020,136:22-25.
[16] Kim K,Maiti A,Kadia TM,et al.Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine[J].Blood,2020,136:33-36.
[17] Liu M,Zhang Y,Zheng W,et al.DAC+CAG Compared with the Standard 3+7Regimen for Induction of the Medically Fit Elderly Acute Myeloid Leukemia:An Open-Label,Multicenter,Randomized,Phase IIITrial[J].Blood,2020,136:23.
[18] Wei AH,D9hner H,Pocock C,et al.Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission[J].N Engl J Med,2020,383(26):2526-2537.
[19] Oliva EN,Kambhampati S,Oriol A,et al.CC-486Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia(AML)in First Remission after Intensive Chemotherapy:Results from the QUAZAR AML-001 Maintenance Trial[J].Blood,2020,136:14-15.
[20] Wei A,Roboz GJ,Dombret H,et al.CC-486Improves Overall Survival(OS)and Relapse-Free Survival(RFS)for Patients with Acute Myeloid Leukemia(AML)in First Remission after Intensive Chemotherapy(IC),Regardless of Amount of Consolidation Received:Results from the Phase III QUAZAR AML-001Maintenance Trial[J].Blood,2020,136:38-40.
[21] DiNardo CD,Jonas BA,Pullarkat V,et al.Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia[J].N Engl J Med,2020,383(7):617-629.
[22] Konopleva M,Thirman M,Pratz KW,et al.Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations[J].Blood,2020,136:8-10.
[23] Pollyea DA,Dinardo CD,Arellano ML,et al.Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations[J].Blood,2020,136:5-7.
[24] Donnellan W,Xu T,Ma E,et al.Use of Venetoclax(VEN)and Hypomethylating Agents(HMA)in Newly Diagnosed Acute Myeloid Leukemia(AML)in the United States(US)-Real World (RW)Response,Treatment Duration,Dose and Schedule Modifications[J].Blood,2020,136:11-12.
[25] Pollyea DA,Bixby D,Perl A,et al.NCCN Guidelines Insights:Acute Myeloid Leukemia,Version 2.2021[J].J Natl Compr Canc Netw,2021,19(1):16-27.
[26] Wei AH,Montesinos P,Ivanov V,et al.Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy:aphase 3randomized placebo-controlled trial[J].Blood,2020,135:2137-2145.
[27] Kennedy VE,Hui G,Gaut D,et al.Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia[J].Blood,2020,136:32-33.
[28] Miller J,Shannon L,Finch A,et al.Venetoclax in Combination with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia Is Comparable to Alternative Regimens[J].Blood,2020,136:3-5.
[29] Kent A,Pollyea DA,Winters A,et al.Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse[J].Blood,2020,136:11-12.
[30] Roboz GJ,DiNardo CD,Stein EM,et al.Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia[J].Blood,2020,135:463-471.
[31] DiNardo CD,Stein AS,Stein EM,et al.Mutant Isocitrate Dehydrogenase 1Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia[J].J Clin Oncol,2021,39(1):57-65.
[32] Stein EM,Huang Y,Borate U,et al.Enasidenib(ENA)Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia(AML):A Completed Phase 2/1bSub-Study of the Beat AML Master Trial[J].Blood,2020,136:27-30.
[33] Stein EM,DiNardo CD,Fathi AT,et al.Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML:aphase 1study[J].Blood,2021,137(13):1792-1803.
[34] Perl AE,Martinelli G,Cortes JE,et al.Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML[J].N Engl J Med,2019,381(18):1728-1740.
[35] Sierra J,Montesinos P,Thomas X,et al.Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed,FLT3-Mutated Acute Myeloid Leukemia(AML)Who Are Eligible for 7+3or 5+2Chemotherapy[J].Blood,2020,136:23-24.
[36] Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML[J].Oncologist,2021,26Suppl 1:S10.
[37] Daver N,Altman J K,Maly J,et al.Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study[J].Blood,2020,136:20-22.
[38] Garcia JS,Flamand Y,Tomlinson BK,et al.Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Na6ve Settings[J].Blood,2020,136:15-17.
[39] Kurosawa S,Yamaguchi T,Uchida N,et al.Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3acute myelogenous leukemia in first complete remission[J].Biol Blood Marrow Transplant,2011,17(3):401-11.
[40] 中华医学会血液学分会白血病淋巴瘤学组.成人急性髓系白血病(非APL)中国诊疗指南(2017年版)[J].中华血液学杂志,2017,38(3):177-182.
[41] Guo M,Chao NJ,Li JY,et al.HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia:Results From the Microtransplantation Interest Group[J].JAMA Oncol,2018,4(1):54-62.
[42] Pan B,Lazarus HM,Gale RP.Microtransplantation for Acute Myeloid Leukemia:A Systematic Review[J].JAMA Oncol,2020,6(10):1614-1620.
-
计量
- 文章访问数: 356
- PDF下载数: 0
- 施引文献: 0
下载: